Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)

NCT07214311 is registered in ClinicalTrials.gov with Peptilogics as lead sponsor.

NCT NCT07214311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07214311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RETAIN: A Phase 2/3 Randomized, Placebo-Controlled Study to Evaluate the Efficacy of PLG0206 in Prevention of Recurrent Infection in Patients Undergoing Debridement, Antibiotics, and Implant Retention (DAIR) for Treatment of a Periprosthetic Joint Infection (PJI) Following Total Knee Arthroplasty (TKA)
Lead sponsor
Peptilogics
Phase
Phase 2/3
Overall status
Recruiting
Start date
February 3, 2026
Completion date
September 30, 2028
Enrollment
240 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

prosthetic-joint infection